Literature DB >> 9971763

Acute effects of pathogenic simian-human immunodeficiency virus challenge on vaccine-induced cellular and humoral immune responses to Gag in rhesus macaques.

K K Steger1, P M Waterman, C D Pauza.   

Abstract

Simian-human immunodeficiency virus (SHIV) infection in macaques provides a convenient model for testing vaccine efficacy and for understanding viral pathogenesis in AIDS. We immunized macaques with recombinant, Salmonella typhimurium (expressing Gag) or soluble Gag in adjuvant to generate T-cell-dependent lymphoproliferative or serum antibody responses. Immunized animals were challenged by intrarectal inoculation with SHIV89.6PD. Virus infection was accompanied by rapid losses of lymphoproliferative responses to Gag or phytohemagglutinin. By 8 weeks, mitogen responses recovered to near normal levels but antigen-specific immunity remained at low or undetectable levels. Serum antibody levels were elevated initially by virus exposure but soon dropped well below levels achieved by immunization. Our studies show a rapid depletion of preexisting Gag-specific CD4(+) T cells that prevent or limit subsequent antiviral cellular and humoral immune responses during acute SHIV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9971763      PMCID: PMC104425     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.

Authors:  G Zwart; L van der Hoek; M Valk; M T Cornelissen; E Baan; J Dekker; M Koot; C L Kuiken; J Goudsmit
Journal:  Virology       Date:  1994-06       Impact factor: 3.616

2.  Pathogenic and protective correlates of T cell proliferation in AIDS. HNRC Group. HIV Neurobehavioral Research Center.

Authors:  R D Schrier; C A Wiley; C Spina; J A McCutchan; I Grant
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.

Authors:  M Clerici; N I Stocks; R A Zajac; R N Boswell; D R Lucey; C S Via; G M Shearer
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

4.  An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys.

Authors:  K A Reimann; J T Li; G Voss; C Lekutis; K Tenner-Racz; P Racz; W Lin; D C Montefiori; D E Lee-Parritz; Y Lu; R G Collman; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Pathogenesis of SIVmac251 after atraumatic inoculation of the rectal mucosa in rhesus monkeys.

Authors:  C D Pauza; P Emau; M S Salvato; P Trivedi; D MacKenzie; M Malkovsky; H Uno; K T Schultz
Journal:  J Med Primatol       Date:  1993 Feb-May       Impact factor: 0.667

6.  Selective amplification of simian immunodeficiency virus genotypes after intrarectal inoculation of rhesus monkeys.

Authors:  P Trivedi; K K Meyer; D N Streblow; B L Preuninger; K T Schultz; C D Pauza
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

7.  Recombinant, attenuated Salmonella typhimurium stimulate lymphoproliferative responses to SIV capsid antigen in rhesus macaques.

Authors:  K K Steger; P J Valentine; F Heffron; M So; C D Pauza
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

8.  Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men.

Authors:  P T Schellekens; M T Roos; F De Wolf; J M Lange; F Miedema
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

9.  Limiting dilution analysis of interleukin-2-producing T cells responsive to recall and alloantigens in human immunodeficiency virus-infected and uninfected individuals.

Authors:  R D Schulick; M Clerici; M J Dolan; G M Shearer
Journal:  Eur J Immunol       Date:  1993-02       Impact factor: 5.532

10.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

Authors:  K A Reimann; J T Li; R Veazey; M Halloran; I W Park; G B Karlsson; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  6 in total

1.  Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.

Authors:  Andreas Mörner; Marianne Jansson; Evelien M Bunnik; Jørgen Schøller; Robert Vaughan; Yufei Wang; David C Montefiori; Nel Otting; Ronald Bontrop; Lesley A Bergmeier; Mahavir Singh; Richard T Wyatt; Hanneke Schuitemaker; Gunnel Biberfeld; Rigmor Thorstensson; Thomas Lehner
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

2.  Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity.

Authors:  M T Shata; D M Hone
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Lymphocyte activation during acute simian/human immunodeficiency virus SHIV(89.6PD) infection in macaques.

Authors:  M Wallace; P M Waterman; J L Mitchen; M Djavani; C Brown; P Trivedi; D Horejsh; M Dykhuizen; M Kitabwalla; C D Pauza
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus.

Authors:  Bhawna Poonia; Maria S Salvato; Hideo Yagita; Toshihiro Maeda; Ko Okumura; C David Pauza
Journal:  Blood       Date:  2009-06-04       Impact factor: 22.113

5.  Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.

Authors:  C D Pauza; P Trivedi; M Wallace; T J Ruckwardt; H Le Buanec; W Lu; B Bizzini; A Burny; D Zagury; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

Review 6.  Polyphosphazene immunoadjuvants: Historical perspective and recent advances.

Authors:  Alexander K Andrianov; Robert Langer
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.